EXACT Sciences Earnings Calls

Q1 2025 Beat
-$0.210 (43.24%)
Release date May 01, 2025
EPS estimate -$0.370
EPS actual -$0.210
EPS Surprise 43.24%
Revenue estimate 688.626M
Revenue actual 706.785M
Revenue Surprise 2.64%
Q4 2024 Beat
-$0.0600 (79.31%)
Release date Feb 19, 2025
EPS estimate -$0.290
EPS actual -$0.0600
EPS Surprise 79.31%
Revenue estimate 697.887M
Revenue actual 713.424M
Revenue Surprise 2.23%
Q3 2024 Missed
-$0.210 (-7.20%)
Release date Nov 05, 2024
EPS estimate -$0.196
EPS actual -$0.210
EPS Surprise -7.20%
Revenue estimate 716.801M
Revenue actual 708.655M
Revenue Surprise -1.14%
Q2 2024 Beat
-$0.0900 (75.68%)
Release date Jul 31, 2024
EPS estimate -$0.370
EPS actual -$0.0900
EPS Surprise 75.68%
Revenue estimate 690M
Revenue actual 699.264M
Revenue Surprise 1.34%

Last 4 Quarters for EXACT Sciences

Below you can see how EXAS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.

Q2 2024 Beat
Release date Jul 31, 2024
Fiscal end date Jun 30, 2024
Price on release $45.68
EPS estimate -$0.370
EPS actual -$0.0900
EPS surprise 75.68%
Date Price
Jul 25, 2024 $48.36
Jul 26, 2024 $45.30
Jul 29, 2024 $45.56
Jul 30, 2024 $46.58
Jul 31, 2024 $45.68
Aug 01, 2024 $57.91
Aug 02, 2024 $57.35
Aug 05, 2024 $55.77
Aug 06, 2024 $55.96
4 days before -5.54%
4 days after 22.50%
On release day 26.77%
Change in period 15.72%
Q3 2024 Missed
Release date Nov 05, 2024
Fiscal end date Sep 30, 2024
Price on release $71.51
EPS estimate -$0.196
EPS actual -$0.210
EPS surprise -7.20%
Date Price
Oct 30, 2024 $70.46
Oct 31, 2024 $68.93
Nov 01, 2024 $69.80
Nov 04, 2024 $71.13
Nov 05, 2024 $71.51
Nov 06, 2024 $54.72
Nov 07, 2024 $53.23
Nov 08, 2024 $51.48
Nov 11, 2024 $51.33
4 days before 1.49%
4 days after -28.22%
On release day -23.48%
Change in period -27.15%
Q4 2024 Beat
Release date Feb 19, 2025
Fiscal end date Dec 31, 2024
Price on release $50.48
EPS estimate -$0.290
EPS actual -$0.0600
EPS surprise 79.31%
Date Price
Feb 12, 2025 $50.34
Feb 13, 2025 $50.59
Feb 14, 2025 $49.31
Feb 18, 2025 $49.63
Feb 19, 2025 $50.48
Feb 20, 2025 $49.51
Feb 21, 2025 $49.26
Feb 24, 2025 $51.28
Feb 25, 2025 $50.18
4 days before 0.278%
4 days after -0.594%
On release day -1.92%
Change in period -0.318%
Q1 2025 Beat
Release date May 01, 2025
Fiscal end date Mar 31, 2025
Price on release $47.16
EPS estimate -$0.370
EPS actual -$0.210
EPS surprise 43.24%
Date Price
Apr 25, 2025 $45.46
Apr 28, 2025 $45.59
Apr 29, 2025 $44.79
Apr 30, 2025 $45.64
May 01, 2025 $47.16
May 02, 2025 $51.55
May 05, 2025 $53.33
May 06, 2025 $53.99
May 07, 2025 $53.28
4 days before 3.74%
4 days after 12.98%
On release day 9.31%
Change in period 17.20%

EXACT Sciences Earnings Call Transcript Summary of Q1 2025

Exact Sciences First Quarter 2025 Earnings Call Summary for Investors

Company Overview: Exact Sciences reported strong financial results for Q1 2025 with notable achievements in screening and revenue growth, alongside significant operational improvements.

Key Highlights:

  • Test Volume and Revenue Growth:
    • Delivered 1.2 million test results to patients in Q1.
    • Core revenue grew by 11%, while non-GAAP operating expenses increased by only 4%, leading to improved profitability with adjusted EBITDA rising over 60%.
  • Product Launches:
    • Launched Cologuard Plus, a next-generation colorectal cancer screening test, which has received Medicare coverage.
    • The company also introduced Oncodetect, a molecular residual disease test, expanding its precision oncology portfolio.
  • Market Engagement:
    • Strengthened commercial initiatives are driving engagement with healthcare providers. Customer satisfaction is reportedly at an all-time high, and customer-initiated ordering has increased dramatically.
    • Cologuard’s brand awareness is reportedly exceeding that of traditional colonoscopies.
  • Financial Performance:
    • Screening revenue reached $540 million, exceeding guidance with a 14% increase.
    • Precision oncology revenue also surpassed expectations, marking a 4% increase to $167 million.
    • Adjusted EBITDA margin expanded, with actions taken to optimize costs leading to projected annual savings of $18 million.
  • Guidance Updates:
    • Total revenue guidance for FY2025 increased to between $3.07 billion and $3.12 billion.
    • Adjusted EBITDA guidance raised to between $425 million to $455 million.
    • Specific guidance for Q2 forecasts total revenue between $765 million and $780 million, with screening revenue between $595 million and $605 million.
  • Strategic Focus and Improvements:
    • Management highlighted ongoing operational efficiency initiatives and emphasized a focus on the high-volume engagement of their field teams.
    • The Rescreen program and care gap initiatives are contributing significantly to predictable revenue growth.
  • Future Product Potential:
    • Launch strategy for Cologuard Plus includes a push towards its adoption as the first-line screening option over colonoscopy.
    • Preparations are underway for the anticipated blood test results expected in the summer, promising innovation in cancer detection.
  • Capital Allocation and Financial Health:
    • The company ended the quarter with $786 million in cash and securities after paying down a $249 million convertible note.
    • Exact Sciences is positioned to utilize its improving financial profile for organic growth investment and potential M&A opportunities in the future.

Investor Implications:

  • Strong growth momentum in revenue and adjusted EBITDA indicates a robust financial outlook and operational capability.
  • Continued innovation in product offerings, combined with an effective commercial strategy, may enhance market share and investor confidence.
  • Watch for updates on payer coverage for Cologuard Plus and the rollout of new products, as these will be critical for future growth trajectories.

Investors should remain attentive to how Exact leverages its commercial improvements and product launches in the rapidly evolving healthcare landscape, particularly as it aims to transition more patients towards its innovative screening solutions.

EXACT Sciences Earnings History

Earnings Calendar

FAQ

When is the earnings report for EXAS?
EXACT Sciences Corporation (EXAS) has scheduled its earnings report for Jul 30, 2025 after the markets close.

What is the EXAS price-to-earnings (P/E) ratio?
EXAS P/E ratio as of May 16, 2025 (TTM) is -10.05.

What is the EXAS EPS forecast?
The forecasted EPS (Earnings Per Share) for EXACT Sciences Corporation (EXAS) for the first fiscal quarter 2025 is -$0.0800.

What are EXACT Sciences Corporation's retained earnings?
On its balance sheet, EXACT Sciences Corporation reported retained earnings of $706.79 million for the latest quarter ending Mar 31, 2025.

What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.

Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.

What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Click to get the best stock tips daily for free!
ABOUT EXACT SCIENCES CORPORATION
EXACT Sciences
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...
GOLDEN STAR
Ticker Change Signal Date
IEP
$8.75
11.43% May 09
JLL
$229.63
2.75% May 09
UAA
$5.84
14.90% May 09
IIPR
$54.61
4.30% May 09
MEDP
$300.81
1.61% May 08

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE